Newly-Listed TC Biopharm Highlights Early Data From Acute Myeloid Leukemia Trial

TC Biopharm Ltd TCBP has announced interim data from Phase 1a/2b of TCB-002, OmnImmune in relapsed/refractory Acute Myeloid Leukemia (AML).
TCB-002 is the Company's allogeneic unmodified gamma delta t-cell product.
Seven patients received treatment, with three receiving a low dose of OmnImmune and four receiving a higher dose of OmnImmune.
In the low dose cohort, one patient achieved MLFS (morphologic leukemia-free state), one patient achieved stable disease characterized as a near-complete response.
One patient met safety endpoints but was lost to follow-up due to co-morbidity (bilateral pneumonia unrelated to OmnImmune treatment).
In the higher dose cohort, 50% of patients achieved complete responses. One patient had progressive disease, and one exhibited significantly reduced cancer blast count at day fourteen (before the study was cut short due to Covid 19).
Allogeneic gamma-delta T cell persistence was evaluated in two patients treated. The allogenic product remained detectable in one patient after 100 days following three infusions.
Another patient demonstrated hematological recovery with a sustained elevation in crucial immune cells over 100 days following the initial infusion.
The Company will report additional Phase 2/3 trial data during 1H of 2022.
In 2022, the Company plans to evaluate OmnImmune efficacy in unresponsive first-line treatment of AML patients.
Price Action: TCBP shares are up 3.41% at $0.97 during the market session on the last check Tuesday.